期刊文献+

实时定量PCR检测BCR-ABL(P210)转录本水平室内长期质控体系的建立及应用 被引量:4

The establishment and application of internal quality control system for real-time quantitative PCR detection of BCR-ABL (P210)
原文传递
导出
摘要 目的制备BCR-ABL(P210)实时定量PCR(RQ-PCR)检测的室内质控物,建立RQ-PCR检测BCR-ABL(P210)转录本水平的室内质控方法。方法取K562细胞和HL-60细胞,制备RQ-PCR检测BCR-ABL(P210)转录本水平的高、低浓度质控物,2013年8月至2015年10月用RQ-PCR法与临床标本同步检}!测BCR-ABL(P210)184次,按试剂批号(批号20130303、20131212、20140411和20150327分别简称为R1、R2、R3、R4)统计分析标准曲线斜率、截距及相关系数,并按试剂批号和质控物批号(批号20130725、20140611分别简称为Q1、Q2)统计分析高、低浓度质控物检测结果,对斜率、截距及质控物检测结果采取Levey-Jennings质控图结合Westgard多规则质控方法进行质控判断。结果①标准曲线斜率、截距:R1检测53次,斜率、截距均未失控;R2检测37次,斜率失控6次,且第2-8次在x-s限值下侧,第12~37次在x值上侧,截距失控9次,且第1-8次在x+s限值上侧,第12~37次出现在i值下侧;R3检测80次和R4检测14次,斜率、截距均未失控。②质控物结果:Q1批号质控物,R1检测49次朱失控,R2检测23次失控1次;Q2批号质控物,R2检测14次、R3检测72次及R4检测14次均未失控。结论利用K562细胞和HL-60细胞制备定量检测BCR-ABL(P210)转录本水平的高、低浓度室内质控物,制备方便,检测结果可靠、稳定,使用质控物检测结果结合标准曲线斜率、截距进行室内质控,可更有效地保证临床检测结果的准确性和稳定性。 Objective To set internal quality control system of BCR-ABL (P210) transcript levels for real-time quantitative PCR (RQ-PCR). Methods Using K562 cells and HL-60 cells, we prepared high- and low-level BCR-ABL internal quality control substance. The BCR-ABL (P210) transcript levels of internal quality control substance have been determined for 184 times together with clinical samples from August 2013 to October 2015. The slope rate, intercept and correlation coefficient of standard curve were calculated according to different reagent lots (lots number 20130303, 20131212, 20140411 and 20150327 are called RI ,R2 ,R3 and R4 for short respectively), and the detection results of quality control substance were calculated according to different reagent lots and quality control substance lots (lots number 20130725, 20140611 are called Q1 ,Q2 for short respectively). Then the results were analyzed by Levey-Jennings quality control chart combined with Westgard multi-rules theory. Results (1)We analyzed the slope rate and intercept of standard curve. Fifty-three times of the R1 reagent detection, 80 times of the R3 reagent detection and 14 times of the R4 reagent detection were all under control. For 37 times detection of R2 reagent, the slope rate was out of control for 6 times. It was lower than x-s for the 2-8 tests and upper the average for the 12-37 tests. The intercept was out of control for 9 times, upper the x+s for the 1-8 tests and lower the average for the 12-37 tests. (2)According to the detection results of quality controlsubstance, for QI quality control substance, 49 tests by R1 reagent were under control, and 1 out of 23 tests by R2 reagent was out of control. For Q2 quality control substance, 14 tests by R2 reagent detection, 72 tests by R3 reagent detection and 14 tests by R4 reagent were all under control. Conclusion The preparation of high- and low-level quality control substance using K562 and HL-60 cells was convenient and the detection results were reliable and stable. The application of quality control substance combined with slope rate and intercept in the internal quality control may contribute to quality assurance for quantitative detection ofBCR-ABL (P210) transcript levels.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第9期800-806,共7页 Chinese Journal of Hematology
基金 国家自然科学基金(81470319)
关键词 实时聚合酶链反应 融合蛋白质类 BCR-ABL 室内质量控制 斜率 截距 Real-time polymerase chain reaction Fusion proteins, BCR-ABL Internal qualitycontrol Slope rate Intercept
  • 相关文献

参考文献22

  • 1Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia [J]. Hematology Am Soc Hematol Educ Program, 2003:132- 152.
  • 2Press RD, Love Z, Tronnes AA, et al. BCR-ABL rnRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML [J]. Blood, 2006, 107 (11):4250-4256.
  • 3Branford S, Fletcher L, Cross NC, et al. Desirable performancecharacteristics for BCR-ABL measurement on an intemational reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clini- cal trials [J]. Blood, 2008, 112 (8):3330-3338.
  • 4秦亚溱.慢性髓性白血病分子学监测国际标准化的意义[J].中华血液学杂志,2014,35(2):102-103. 被引量:2
  • 5秦亚溱,程辉,岑建农,耿素霞,李庆华,李小青,林振兴,马道新,乔纯,王云贵,李金兰,李玲娣,黄晓军.定量检测bcr—abl(P210)转录本水平多中心比对研究[J].中华血液学杂志,2013,34(2):104-108. 被引量:11
  • 6秦亚溱,林振兴,岑建农,李小青,李庆华,程辉,耿素霞,王云贵,马道新,乔纯,李金兰,李玲娣,黄晓军.用于转换国际标准的BCR-ABL(P210)转录本水平的转换系数多中心确认研究[J].中华血液学杂志,2014,35(2):134-137. 被引量:13
  • 7Mfiller MC, Cross NC, Erben P, et al. Harmonization of molecu- lar monitoring of CML therapy in Europe [J]. Leukemia, 2009, 23( 11 ):1957-1963.
  • 8Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results [J]. Blood, 2006, 108( 1 ):28-37.
  • 9Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program [J]. Leukemia, 2003, 17 (12):2318- 2357.
  • 10Stanoszek LM, Crawford EL, Blomquist TM, et al. Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples[J]. J Mol Diagn, 2013, 15(3):391- 400.

二级参考文献55

  • 1许川山,余茜,刘志君.激光及光化学法在基因转染中的作用[J].激光杂志,2004,25(4):95-95. 被引量:4
  • 2沈伟锋,丁韧烨,杨清萍,邵平扬.荧光定量PCR测定HBVDNA的不确定度评定与应用[J].中华检验医学杂志,2007,30(2):169-172. 被引量:13
  • 3任广睦,王英元.实时荧光定量PCR技术的研究进展[J].临床医药实践,2007,16(4):243-245. 被引量:9
  • 4秦亚溱,李金兰,主鸿鹄,李玲娣,常艳,郝乐,阮国瑞,刘艳荣,黄晓军,陈珊珊.实时定量RT-PCR技术测定初治白血病患者常见融合基因转录子水平及其标准化的探讨[J].中华血液学杂志,2007,28(7):433-437. 被引量:27
  • 5李志敏 侯斌.Excel 2000即学即用[M].北京:科学出版社,1999..
  • 6Stam K, Heisterkamp N, Grosveld G, et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leu- kemia and the Philadelphia chromosome. N Engl J Med, 1985, 313 : 1429-1433.
  • 7Baccarani M, Saglio G, Goldman J, et ak Evolving concepts in the management of chronic myeloid leukemia:recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006,108 : 1809-1820.
  • 8Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML pa- tients responding to treatment with tyrosine kinase inhibitors : re- view and recommendations for harmonizing current methodology fordetecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood,2006,108:28-37.
  • 9Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemi- a,1999,13:1525-1832.
  • 10Branford S, Fletcher L, Cross NC, et al. Desirable perfommnce characteristics for BCR-ABL measurement on an international re- porting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 2008,112:3330-3338.

共引文献148

同被引文献18

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部